about
3'-Azido-3'-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitroConstruction of recombinant murine retroviruses that express the human T-cell leukemia virus type II and human T-cell lymphotropic virus type III trans activator genesRetroviral coinfections: HIV and HTLV: taking stock of more than a quarter century of researchStructural and biochemical characterization of the inhibitor complexes of xenotropic murine leukemia virus-related virus proteaseComparisons of anti-human immunodeficiency virus activities, cellular transport, and plasma and intracellular pharmacokinetics of 3'-fluoro-3'-deoxythymidine and 3'-azido-3'-deoxythymidineSynergistic inhibition of human immunodeficiency virus type 1 replication in vitro by two-drug and three-drug combinations of 3'-azido-3'-deoxythymidine, phosphonoformate, and 2',3'-dideoxythymidineActivities of (-)-carbovir and 3'-azido-3'-deoxythymidine against human immunodeficiency virus in vitroInhibition of the in vitro infectivity and cytopathic effect of human T-lymphotrophic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV) by 2',3'-dideoxynucleosidesRibonuclease H/DNA Polymerase HIV-1 Reverse Transcriptase Dual Inhibitor: Mechanistic Studies on the Allosteric Mode of Action of Isatin-Based Compound RMNC6Recent Insights into the HIV/AIDS Pandemic.In vitro and in vivo evidence that the antiviral activity of 2',3'-dideoxycytidine is target cell dependent in a feline retrovirus animal model.Human immunodeficiency virus infection in childhood.Inhibition of HIV-1 entry by extracts derived from traditional Chinese medicinal herbal plantsFactors affecting seropositivity to human T cell lymphotropic virus type III (HTLV-III) or lymphadenopathy associated virus (LAV) and progression of disease in sexual partners of patients with AIDSTranscriptional activation of homologous viral long terminal repeats by the human immunodeficiency virus type 1 or the human T-cell leukemia virus type I tat proteins occurs in the absence of de novo protein synthesis.Antibodies to CD4 in individuals infected with human immunodeficiency virus type 1.Construction and use of a replication-competent human immunodeficiency virus (HIV-1) that expresses the chloramphenicol acetyltransferase enzyme.Innate immune recognition and activation during HIV infection.Oral infectious diseases: a potential risk factor for HIV virus recrudescence?Toll-like receptor 7 controls the anti-retroviral germinal center responsePneumonia in the acquired immune deficiency syndrome.Mechanisms of B cell activation in patients with acquired immunodeficiency syndrome and related disorders. Contribution of antibody-producing B cells, of Epstein-Barr virus-infected B cells, and of immunoglobulin production induced by human T cell lNeuropsychiatric Effects of HIV Antiviral Medications.Demonstration of defective C3-receptor-mediated clearance by the reticuloendothelial system in patients with acquired immunodeficiency syndrome.Long-term inhibition of human T-lymphotropic virus type III/lymphadenopathy-associated virus (human immunodeficiency virus) DNA synthesis and RNA expression in T cells protected by 2',3'-dideoxynucleosides in vitro.Prematurity, hypogammaglobulinemia, and neuropathology with human immunodeficiency virus (HIV) infection.Human T-cell lymphotropic virus IIIB glycoprotein (gp120) bound to CD4 determinants on normal lymphocytes and expressed by infected cells serves as target for immune attackLitsea Species as Potential Antiviral Plant Sources.A guide to the investigation and treatment of patients with AIDS and AIDS-related disordersCDC's Model Performance Evaluation Program: assessment of the quality of laboratory performance for HIV-1 antibody testingEmergence of aminoglycoside resistance genes aadA and aadE in the genus CampylobacterHuman T cell leukemia virus-I-associated T-suppressor cell inhibition of erythropoiesis in a patient with pure red cell aplasia and chronic T gamma-lymphoproliferative disease."One pill, once daily": what clinicians need to know about Atriplatrade mark.Synthesis of functional human immunodeficiency virus tat protein in baculovirus as determined by a cell-cell fusion assay.Indirect immunofluorescence test performance and questionnaire results from the Centers for Disease Control Model Performance Evaluation Program for human immunodeficiency virus type 1 testing.In vitro modification of human immunodeficiency virus infection by granulocyte-macrophage colony-stimulating factor and gamma interferon.Stimulatory and inhibitory influences of human immunodeficiency virus on normal B lymphocytes.Isolation of infectious human T-cell leukemia/lymphotropic virus type III (HTLV-III) from patients with acquired immunodeficiency syndrome (AIDS) or AIDS-related complex (ARC) and from healthy carriers: a study of risk groups and tissue sources.Influence of the human T-lymphotropic virus/lymphadenopathy-associated virus on functions of human lymphocytes: evidence for immunosuppressive effects and polyclonal B-cell activation by banded viral preparations.Preformulation studies of Zidovudine derivatives: Acid dissociation constants, differential scanning calorimetry, thermogravimetry, x-ray powder diffractometry and aqueous stability studies
P2860
Q24609215-909F2E51-57A2-4663-8444-08DC1632CF3EQ24655892-9C213D92-0F4B-4AE1-9E87-D339F001B18BQ26853678-DC5DC08A-788E-4A1A-8D4C-E6E153707EFEQ27674531-4CD0BB30-9579-4F1E-97FB-A4632DB22D8CQ28318354-C1679DD1-4C39-4921-90E2-7AD39A8AEF20Q28324208-51900CA9-B4DC-4751-B1B7-F06697F23ED7Q28335926-D33DBC44-C75E-49BC-BB1F-A4220FC127C7Q28360374-40E5D702-880B-4081-B6FC-AAAE1F0BA0EFQ28552768-13053CA8-C4B3-474E-A58F-7C99BA9204F4Q30235024-137F4667-E332-41B8-AC56-99919F8FAB97Q33395770-117CBB0C-7982-4057-827E-5543D13180CDQ33413501-7CC1C647-D4F8-44BD-8FFC-C5F14689788EQ33490833-60461E63-7D0E-4057-9C62-C0DAD6C3158BQ33583156-74098EC4-5A77-4112-A36D-14D9F7E521B9Q33666139-B4048FC3-0EF1-4BD9-845F-7D3349456347Q33854440-6DAF74B6-AFB2-44FB-BEB0-DD41D6ABFC17Q33859324-7F1867E4-8451-4567-9E67-514C6193B822Q33997880-A8DD5AB0-F658-44AE-96C9-F07DACDE09CCQ34038531-2FC5FBF9-8367-44A2-B0EA-191BD9CA1359Q34048099-D5B6C0BB-0E5D-4450-B457-038FE233F81CQ34484229-DF03DA7F-B706-4CF8-BDBC-21B505174167Q34533784-B590F4BC-8419-4C51-B680-6FCBB151D3A1Q34537705-AE47B84E-F49B-4ED5-89B2-324E8CD8C9B8Q34562918-58B7A961-24B9-43B0-AFC0-48BD3A635C05Q34610200-E88F3694-08E4-4AE5-8010-AEFFB006055AQ34628378-8AC1F956-8A8C-4587-A2CE-34491680B03AQ34636237-AE2453ED-253B-4286-9DFA-62B6D4867A99Q34676915-75E9FF30-B19D-4739-B3E5-A40257489F2DQ34728008-9A566276-7988-4703-B163-04A2E9919E0AQ35054727-9DE84882-8371-4879-9CC6-D40FEC48CEB2Q35264706-708FA8AE-4319-4740-9748-305098E412F3Q35809969-3C6412E8-E51B-4BFB-B1E2-422BD203EFDEQ36823570-BFCAFE8A-A0C6-4313-A5E8-E910D2B7733BQ36873184-0973946B-9F99-4C8B-A5B8-D44F2961AD1AQ37187940-773375AB-FF3F-4CC1-BFA8-C808E6973897Q37408000-2C10B60D-24D3-40D9-9E16-F28CDD97299CQ37409831-1FC27A3D-89D4-4BB6-A98B-E94253EC105CQ37547112-464720F5-1A77-40B1-9AD7-00C398B0112BQ37557735-060FB28D-0FB0-4881-8A82-2F528659A716Q38268648-A1560070-67A4-44C0-BEF8-82F9E2918BEC
P2860
description
1984 nî lūn-bûn
@nan
1984年の論文
@ja
1984年学术文章
@wuu
1984年学术文章
@zh-cn
1984年学术文章
@zh-hans
1984年学术文章
@zh-my
1984年学术文章
@zh-sg
1984年學術文章
@yue
1984年學術文章
@zh
1984年學術文章
@zh-hant
name
A pathogenic retrovirus (HTLV-III) linked to AIDS.
@en
type
label
A pathogenic retrovirus (HTLV-III) linked to AIDS.
@en
prefLabel
A pathogenic retrovirus (HTLV-III) linked to AIDS.
@en
P1476
A pathogenic retrovirus (HTLV-III) linked to AIDS.
@en
P2093
P304
P356
10.1056/NEJM198411153112006
P407
P50
P577
1984-11-01T00:00:00Z